O'Neill Gilmore Neil sold $51K of EDIT
O'Neill Gilmore Neil (CEO) sold 21,164 shares of Editas Medicine, Inc. (EDIT) at $2.42 on 2026-11-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to move the stock materially.
Market read
A small insider sale with limited market impact; traders may note but no immediate action required.
What to watch
The CEO's holdings remain substantial, reducing the significance of the sale.
Background
Form 4 filings disclose insider transactions; a 10b5-1 plan sale is pre‑arranged and often unrelated to current market conditions.
Ticker impact
CEO O'Neill Gilmore Neil sold 21,164 shares for $51,121 via a 10b5-1 plan, reducing his stake to 265,592 shares.
likely slight pressure as the market prices in the insider sell.
The sale is small relative to float and disclosed via a pre‑arranged plan, limiting actionable impact.
Market effects
Minimal effect on the broader biotech sector.
None
None
Counterpoint
The sale could be routine and not indicative of future performance.
Key entities
- CompanyEditas Medicine, Inc.
Biotech firm developing CRISPR‑based gene editing therapies.
- PersonO'Neill Gilmore Neil
CEO of Editas Medicine.


